Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms

Pathology Research and Practice

Volumn 204, Issue 3, 2008, Pages 163-174

  Giordano, Giovanna ^a   Azzoni, Cinzia ^a   D'Adda, Tiziana ^a   Rocco, Alba ^b   Gnetti, Letizia ^a   Froio, Elisabetta ^a   Merisio, Carla ^c   Melpignano, Mauro ^c  

^a Section of Pathology   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Epithelial ovarian neoplasms; Human papilloma virus (HPV); p16INK4a and p53 immunoreactivity

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; PROTEIN P53; VIRUS DNA;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; OVARY TUMOR; POLYMERASE CHAIN REACTION; PROGNOSIS; THEORY; UNIVARIATE ANALYSIS; WART VIRUS;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39149133970     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.11.001     Document Type: Article

References (62)

1. Alkushi A., Lim P., Coldman A., Huntsman D., Miller D., and Gilks C.B. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int. J. Gynecol. Pathol. 23 (2004) 129-137
2. Armes J.E., Lourie R., de Silva M., Stamaratis G., Boyd A., Kumar B., Price G., Hyde S., Allen D., Grant P., and Venter D.J. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein,. Int. J. Gynecol. Pathol. 24 (2005) 363-368
3. Bargonetti J., and Manfredi J.J. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14 (2002) 86-91
4. Benedet J.L., Bender H., Jones III H., Ngan H.Y., and Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecological cancers. Int. J. Gynecol. Obstet. 70 (2000) 209-262
5. Bosari S., Viale G., Radaelli U., Bossi P., Bonoldi E., and Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum. Pathol. 24 (1993) 1175-1179
6. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., and Weber B.L. BRAF and RAS mutations in human lung cancer melanoma. Cancer Res. 62 (2002) 6997-7000
7. INK4A and Ki-67 proteins in serous ovarian tumors. Exp. Oncol. 29 (2007) 49-53
8. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., and Sidransky D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95 (2003) 625-627
9. Cavuslu S., Goodlad J., Hobbs C., Connor A.M., Raju K.S., Best J.M., and Cason J. Relationship between human papillomavirus infection and overexpression of p53 protein in cervical carcinomas and lymph node metastases. J. Med. Virol. 53 (1997) 111-117
10. Dong Y., Walsh M.D., McGuckin M.A., Gabrielli B.G., Cummings M.C., Wright R.G., Hurst T., Khoo S.K., and Parsons P.G. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int. J. Cancer 74 (1997) 57-63
11. Elishaev E., Gilks C.B., Miller D., Srodon M., Kurman R.J., and Ronnett B.M. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am. J. Surg. Pathol. 29 (2005) 281-294
12. Eltabbakh G.H., Belinson J.L., Kennedy A.W., Biscotti C.V., Casey G., Tubbs R.R., and Blumenson L.E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80 (1997) 892-898
13. Finlay C.A., Hinds P.W., Tan T.H., Eliyahu D., Oren M., and Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell Biol. 8 (1988) 531-539
14. Fujita M., Enomoto T., Haba T., Nakashima R., Sasaki M., Yoshino K., Wada H., Buzard G.S., Matsuzaki N., Wakasa K., and Murata Y. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int. J. Cancer 74 (1997) 148-155
15. Giordano G., D'Adda T., Merisio C., and Gnetti L. Vulvar acantholytic squamous carcinoma: a case report with immunohistochemical, and molecular study. Int. J. Gynecol. Pathol. 24 (2005) 303-306
16. Giordano G., D' Adda T., Gnetti L., Merisio C., and Melpignano M. Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features and emphasis in the HPV status. Int. J. Gynecol. Pathol. 25 (2006) 77-82
17. Giordano G., D' Adda T., Gnetti L., Merisio C., and Melpignano M. Detection of human papillomavirus in organs of upper genital tract in women with cervical cancer. Int. J. Gynecol. Cancer 16 (2006) 1601-1607
18. Giordano G., D'Adda T., Gnetti L., Froio E., and Merisio C. Ruolo dell'HPV nello sviluppo delle neoplasie ovariche epiteliali maligne e a malignita' borderline. Pathologica 98 (2006) 529
19. Grace V.M., Shalini J.V., lekha T.T., Devaraj S.N., and Devaraj H. Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 91 (2003) 51-58
20. Hartman L.C., Podratz K.C., and Kenney G.L. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol. 12 (1994) 64-69
21. Huang L.W., Chou Y.Y., Chao S.L., Chen T.J., and Lee T.T. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol. Oncol. 83 (2001) 348-354
22. Ip S.M., Wong L.C., Xu C.M., Cheung A.N., Tsang P.C., and Ngan H.Y. Detection of human papillomavirus DNA in malignant lesions from Chinese women with carcinomas of the upper genital tract. Gynecol. Oncol. 87 (2002) 104-111
23. Jeffers M.D., Richmond J., Farquharson M., and McNicol A.M. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J. Clin. Pathol. 47 (1994) 1073-1076
24. Keating J.T., Cviko A., Reithdorf S., Riethdorf L., Quade B.J., Sun D., Duensing S., Sheets E.E., Munger K., and Crum C.P. Ki-67, cyclin E and p16 (INK4) are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am. J. Surg. Pathol. 25 (2001) 891-894
25. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Dallenbach-Hellweg G., Schmidt D., and von Knebel Doeberitz M. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92 (2001) 276-284
26. Klaes R., Benner A., Friedrich T., Ridder R., Herrington S., Jenkins D., Kurman R.J., Schmidt D., Stoler M., and von Knebel Doeberitz M. p16 ink4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am. J. Surg. Pathol. 27 (2003) 1284
27. Klemi P.J., Pylkkãnen L., Kiilholma P., Kurvinen K., and Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76 (1995) 1201-1208
28. Kohler M.F., Marks J.R., Wiseman R.W., Jacobs I.J., Davidoff A.M., Clarke-Pearson D.L., Soper J.T., Bast Jr. R.C., and Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst. 85 (1993) 1513-1519
29. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta. 1756 (2005) 81-82
30. Kupryjanczyk J., Thor A.D., Beauchamp R., Merritt V., Edgerton S.M., Bell D.A., and Yandell D.W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA 90 (1993) 4961-4965
31. Kurvinen K., Syrjãnen K., and Syrjãnen S. p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. J. Clin. Oncol. 14 (1996) 2120-2130
32. Lakshmi S., Nair M.B., Jayaprakash P.G., Rajalekshmy T.N., Nair M.K., and Pillai M.R. p53 protein and tumorigenesis in the uterine cervix. Gen. Diagn. Pathol. 142 (1997) 281-287
33. Lai C.H., Hsueh S., Lin C.Y., Huang M.Y., You G.B., Chang H.C., and Pao C.C. Human papillomavirus in benign and malignant ovarian and endometrial tissues. Int. J. Gynecol. Pathol. 11 (1992) 210-215
34. Lai C.H., Wang C.Y., Lin C.Y., and Pao C.C. Detection of human papillomavirus RNA in ovarian and endometrial carcinomas by reverse transcription/polymerase chain reaction. Gynecol. Obstet. Invest. 38 (1994) 276-280
35. Levesque M.A., Katsaros D., Yu H., Zola P., Sismondi P., Giardina G., and Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75 (1995) 1327-1338
36. Levine A.J., Perry M.E., Chang A., Silver A., Dittmer D., Wu M., and Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer 69 (1994) 409-416
37. Li Y., Nichols M.A., Shay J.W., and Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54 (1994) 6078-6082
38. McManus D.T., Yap E.P., Maxwell P., Russell S.E., Toner P.G., and McGee J.O. p53 expression, mutation, and allelic deletion in ovarian cancer. J. Pathol. 174 (1994) 159-168
39. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C., Kelly K.F., Parkin D.E., and Haites N.E. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53 (1993) 2128-2132
40. Murphy N., Bermingham N., and Ring M. Immunocytochemical analysis of p16 protein in cervical cancer and cervical intraepithelial neoplasia. J. Pathol. 195 (2001) 2A
41. Niwa K., Itoh M., Murase T., Morishita S., Itoh N., Mori H., and Tamaya T. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br. J. Cancer 70 (1994) 1191-1197
42. O'Neill C.J., McBride H.A., Connolly L.E., Deavers M.T., Malpica A., and McCluggage W.G. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 50 (2007) 773-779
43. INK4a overexpression is associated with poor clinical outcome in ovarian carcinoma. J. Chemother. 16 (2004) 411-413
44. Reihsaus E., Kohler M., Kraiss S., Oren M., and Montenarh M. Regulation of the level of the oncoprotein p53 in non transformed and transformed cells. Oncogene 5 (1990) 137-145
45. Rogel A., Popliker M., Webb C.G., and Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues,embryos, and tumors. Mol. Cell Biol. 5 (1985) 2851-2855
46. Saegusa M., Machida D., and Okayasu I. Possibile association among expression of p14 ARF, 21 WAF1/CIP1, p27 KIP1, and p53 accumulation and the bilance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 92 (2001) 1177-1189
47. Sano T., Oyama T., Kashiwabara K., Fukuda T., and Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am. J. Pathol. 153 (1998) 1741-1748
48. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
49. Shih IeM, and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164 (2004) 1511-1518
50. Shigemasa K., Hu C., West C.M., Clarke J., Parham G.P., Parmley T.H., Korourian S., Baker V.V., and O'Brien T.J. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J. Soc. Gynecol. Investig. 4 (1997) 95-102
51. Silverberg S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 19 (2000) 7-15
52. Slagle B.L., Kaufman R.H., Reeves W.C., and Icenogle J.P. Expression of ras, c-myc, and p53 proteins in cervical intraepithelial neoplasia. Cancer 83 (1998) 1401-1408
53. Tachibana M., Watanabe J., Matsushima Y., Nishida K., Kobayashi Y., Fujimura M., and Shiromizu K. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: a multivariate analysis of expression of p53, retinoblastoma and related proteins. Int. J. Gynecol. Cancer 13 (2003) 598-606
54. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., and Birrer M.J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53 (1993) 3103-3108
55. Vang R., Gown A.M., Farinola M., Barry T.S., Wheeler D.T., Yemelyanova A., Seidman J.D., Judson K., and Ronnett B.M. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am. J. Surg. Pathol. 31 (2007) 653-663
56. Wen W.H., Reles A., Runnebaum I.B., Sullivan-Halley J., Bernstein L., Jones L.A., Felix J.C., Kreienberg R., el-Naggar A., and Press M.F. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int. J. Gynecol. Pathol. 18 (1999) 29-41
57. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
58. Weinberg R.A. Fewer and fewer oncogenes. Cell 30 (1982) 3-4
59. Werness B.A., Levine A.J., and Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248 (1990) 76-79
60. Williams N.G., and Roberts T.M. Signal transduction pathways involving the Raf proto-oncogene. Cancer Metastasis Rev. 13 (1994) 105-116
61. Wu Q.J., Guo M., Lu Z.M., Li T., Qiao H.Z., and Ke Y. Detection of human papillomavirus-16 in ovarian malignancy. Br. J. Cancer 89 (2003) 672-675
62. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., Futreal P.A., Stratton M.R., Wooster R., and Leung S.Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62 (2002) 6451-6455